A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules.
Hepatitis B (HB) vaccinations given once weekly for 3 weeks can provide early seroprotection. This study compared immune responses induced by the accelerated (A; days 0, 10, 21) and classic (C; days 0, 28, 56) HB vaccination schedules. Two hundred seventy healthy subjects (95 men, 175 women) with a mean age of 23.8 years received 3 doses of GenHevac B, a recombinant vaccine produced in mammalian cells. The subjects were randomly assigned to schedules A or C. A booster dose was given 1 year later. One month after the third dose, 70% (schedule A) and 92% (schedule C) of the subjects were seroprotected and 100% (A) and 99% (C) had developed anti-pre-S2 antibodies. Before booster injections, 93% (A) and 95% (C) of the subjects were seroprotected, and 1 month after the booster, almost all subjects were seroprotected. A 3-week HB vaccination schedule with GenHevac B can confer early protective immunity lasting up to 1 year.
Marchou
B
B
Service des Maladies Infectieuses et Tropicales, Hôpital Purpan, Toulouse, France.
Excler
J L
JL
Bourderioux
C
C
Salaun
J
J
Picot
N
N
Yvonnet
B
B
Cerisier
J E
JE
Salomon
H
H
Auvergnat
J C
JC
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006801:Humans; D007115:Immunization Schedule; D008297:Male; D013997:Time Factors
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines